CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC.

被引：7
|
作者：
Shu, Catherine A.
Goto, Koichi
Cho, Byoung Chul
Griesinger, Frank
Yang, James Chih-Hsin
Felip, Enriqueta
Xie, John
Chen, Jun
Mahoney, Janine
Thayu, Meena
Knoblauch, Roland Elmar
Trani, Leonardo
Bauml, Joshua
机构：
[1] Columbia Univ, Med Ctr, New York, NY USA
[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[3] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[4] Univ Oldenburg, Pius Hosp, Oldenburg, Germany
[5] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan
[6] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[7] Janssen R&D, Spring House, PA USA
[8] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS9132
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9132
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study
    Leighl, N. B.
    Shu, C. A.
    Minchom, A.
    Felip, E.
    Cousin, S.
    Cho, B. C.
    Park, K.
    Han, J-Y.
    Boyer, M.
    Lee, C. K.
    Moreno Garcia, V.
    Tomasini, P.
    Viteri, S.
    Xie, J.
    Mertz, J.
    Artis, E.
    Schnepp, R. W.
    Knoblauch, R. E.
    Thayu, M.
    Trigo Perez, J. M.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S951 - S952
  • [2] A Phase 1/1b Study of Lazertinib as Monotherapy and in Combination with Amivantamab in Advanced EGFR-Mutated NSCLC
    Goto, K.
    Hida, T.
    Funami, N.
    Iwasawa, R.
    Mita, S.
    Botilde, Y.
    Yamashita, A.
    Inoh, Y.
    Haddish-Berhane, N.
    Xie, J.
    Roshak, A.
    Knoblauch, R. E.
    Ohe, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S344 - S345
  • [3] Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC
    Marmarelis, M. E.
    Lee, S. -H.
    Spira, A. I.
    Ou, S. -H. I.
    Waqar, S.
    Li, S.
    Thayu, M.
    Knoblauch, R. E.
    Bauml, J. M.
    Cho, B. C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S68 - S68
  • [4] Analysis of ctDNA next generation sequencing (NGS) for predicting response to amivantamab and lazertinib among patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy (CHRYSALIS-2 Cohort A)
    Sanborn, Rachel E.
    Waqar, Saiama N.
    Cho, Byoung Chul
    Besse, Benjamin
    Goto, Koichi
    Wang, Yongsheng
    Lee, Se-Hoon
    Marmarelis, Melina E.
    Ohe, Yuichiro
    Kim, Dong-Wan
    Calles, Antonio
    Neal, Joel
    Baik, Christina S.
    Janne, Pasi A.
    Curtin, Joshua C.
    Patel, Bharvin
    Gormley, Mike
    Shreeve, S. Martin
    Bauml, Joshua M.
    Knoblauch, Roland E.
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [5] Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2
    Shu, C. A.
    Goto, K.
    Ohe, Y.
    Besse, B.
    Park, K.
    Wang, Y.
    Griesinger, F.
    Yang, J. C-H.
    Felip, E.
    Sanborn, R. E.
    Caro, R. Bernabe
    Bauml, J. M.
    Chen, J.
    Fennema, E.
    Mahoney, J.
    Trani, L.
    Knoblauch, R. E.
    Thayu, M.
    Cho, B. C.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S952 - S953
  • [6] Amivantamab, Lazertinib Plus Platinum-based Chemotherapy in EGFR-mutated Advanced NSCLC: Updated Results from CHRYSALIS-2
    Lee, S. -H.
    Cho, B. C.
    Spira, A. I.
    Ou, S. -H. I.
    Waqar, S. N.
    Shah, S.
    Trani, L.
    Chu, P. -L.
    Thayu, M.
    Knoblauch, R. E.
    Bauml, J. M.
    Marmarelis, M. E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S146 - S147
  • [7] MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab plus Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC
    Shreeve, S. M.
    Martinez, M.
    Verheijen, R. B.
    Xie, J.
    Sun, T.
    Haddish-Berhane, N.
    Curtin, J. C.
    Karkera, J.
    Pang, D.
    Roshak, A.
    Knoblauch, R. E.
    Patel, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S620 - S621
  • [8] Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2
    Cho, Byoung Chul
    Wang, Yongsheng
    Felip, Enriqueta
    Cui, Jiuwei
    Spira, Alexander I.
    Neal, Joel W.
    Baik, Christina
    Marmarelis, Melina Elpi
    Ichihara, Eiki
    Lee, Jong-Seok
    Lee, Se-Hoon
    Yang, James Chih-Hsin
    Michels, Sebastian Yves Friedrich
    Anastasiou, Zacharias
    Curtin, Joshua C.
    Lyu, Xuesong
    Leconte, Isabelle
    Trani, Leonardo
    Baig, Mahadi
    Tomasini, Pascale
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease
    Yu, Helena Alexandra
    Chen, Monica F.
    Hui, Angela B.
    Choudhury, Noura J.
    Lee, Jake June-Koo
    Zheng, Jennifer
    Ahn, Linda Su Hyun
    Pupo, Amanda
    Nesselbush, Monica
    Jabara, Isabel
    Heller, Glenn
    Arbour, Kathryn C.
    Santini, Fernando Costa
    Offin, Michael
    Chaft, Jamie E.
    Young, Robert J.
    Riely, Gregory J.
    Kris, Mark G.
    Diehn, Maximilian
    Boire, Adrienne Ann
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2
    Cho, B. C.
    Wang, Y.
    Li, Y.
    Wu, L.
    Besse, B.
    Marmarelis, M. E.
    Goto, K.
    Lee, J-S.
    Lee, S-H.
    Zhang, Y.
    Neal, J.
    Curtin, J.
    Bauml, J. M.
    Mahoney, J.
    Trani, L.
    Knoblauch, R. E.
    Tomasini, P.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1566 - S1566
12345